Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

30.85USD
10:54am EST
Change (% chg)

$-0.35 (-1.12%)
Prev Close
$31.20
Open
$31.05
Day's High
$31.30
Day's Low
$30.80
Volume
22,403
Avg. Vol
111,231
52-wk High
$37.45
52-wk Low
$18.00

Latest Key Developments (Source: Significant Developments)

Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Revance Therapeutics Inc ::REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS.REVANCE THERAPEUTICS INC - TRIAL'S PRIMARY ENDPOINT SHOWED ROBUST IMPACT ON PAIN, WITH GREATER THAN 50% REDUCTION FOR PATIENTS TREATED WITH RT002.REVANCE THERAPEUTICS INC - RT002 APPEARED TO BE GENERALLY SAFE AND WELL-TOLERATED THROUGH WEEK 8.REVANCE THERAPEUTICS - EXPECT TO CONDUCT ANOTHER PHASE 2A TRIAL WITH MODIFIED DESIGN TO DEMONSTRATE RT002'S ABILITY TO TREAT PLANTAR FASCIITIS.  Full Article

Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018
Thursday, 4 Jan 2018 08:30am EST 

Jan 4 (Reuters) - Revance Therapeutics Inc ::REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018.REVANCE THERAPEUTICS INC - EXPECTS TO COMPLETE RT002 SAKURA PHASE 3 PROGRAM AND START RT002 PHASE 3 TRIAL FOR CERVICAL DYSTONIA IN 2018.REVANCE THERAPEUTICS INC - EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION.REVANCE THERAPEUTICS INC - ANTICIPATES 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSE TO BE IN RANGE OF $84 TO $101 MILLION.  Full Article

Revance Announces Pricing Of Public Offering Of Common Stock
Thursday, 7 Dec 2017 08:30am EST 

Dec 7 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.REVANCE THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $31.00 PER SHARE​.  Full Article

Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​
Tuesday, 5 Dec 2017 05:20pm EST 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​.  Full Article

Revance Announces Proposed Public Offering Of Common Stock
Tuesday, 5 Dec 2017 04:45pm EST 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK.REVANCE THERAPEUTICS INC - CERTAIN STOCKHOLDERS OF CO ARE ALSO OFFERING 600,000 SHARES OF COMPANY'S COMMON STOCK FOR SALE TO PUBLIC.  Full Article

Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials
Tuesday, 5 Dec 2017 07:30am EST 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE’S RT002 MEETS PRIMARY AND ALL SECONDARY ENDPOINTS, ACHIEVES 6-MONTH DURATION IN PIVOTAL SAKURA PHASE 3 TRIALS FOR GLABELLAR LINES.SAYS RT002 DELIVERED HIGHLY STATISTICALLY SIGNIFICANT REDUCTION IN SEVERITY OF GLABELLAR LINES AT WEEK 24.SAYS RT002 DELIVERED POSITIVE TOP-LINE RESULTS IN ALLEVIATING MODERATE-TO-SEVERE GLABELLAR LINES IN 2 PIVOTAL SAKURA PHASE 3 TRIALS.SAYS RT002 APPEARED GENERALLY SAFE AND WELL-TOLERATED IN BOTH STUDIES.SAYS ASSUMING SUCCESSFUL COMPLETION OF SAKURA 3, COMPANY PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION IN FIRST HALF OF 2019.SAYS LONG-TERM SAFETY TRIAL, SAKURA 3, IS FULLY ENROLLED AND IS EXPECTED TO BE COMPLETED IN SECOND HALF OF 2018.SAYS COMPANY PLANS TO LAUNCH RT002 IN U.S. IN 2020, PENDING APPROVAL BY FDA.  Full Article

Revance Plans Phase 3 Program For RT002 Injectable To Treat Cervical Dystonia
Wednesday, 29 Nov 2017 04:05pm EST 

Nov 29 (Reuters) - Revance Therapeutics Inc ::REVANCE PLANS PHASE 3 PROGRAM FOR RT002 INJECTABLE TO TREAT CERVICAL DYSTONIA.REVANCE THERAPEUTICS INC - COMPANY COMPLETES END-OF-PHASE 2 MEETING WITH FDA.REVANCE THERAPEUTICS - FINALIZING TRIAL PROTOCOLS FOR PIVOTAL RT002 PROGRAM, WHICH IS PLANNED TO COMMENCE IN Q2 2018.  Full Article

Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia
Monday, 20 Nov 2017 04:05pm EST 

Nov 20 (Reuters) - Revance Therapeutics Inc :Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia.Revance Therapeutics Inc - ‍U.S. FDA granted orphan drug designation for Co's product candidate, Daxibotulinumtoxina for injection (RT002)​.  Full Article

Revance Therapeutics reports qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Revance Therapeutics Inc :Revance releases third quarter 2017 results.Revance Therapeutics Inc - ‍sakura 1 & 2 phase 3 pivotal trials on track to report topline results before year-end 2017​.Revance Therapeutics Inc - ‍expects to complete sakura open-label safety phase 3 study of rt002 injectable for treatment of glabellar lines in h2 2018​.Revance Therapeutics Inc - ‍reaffirmed financial guidance provided in january 2017​.Revance Therapeutics Inc qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01.  Full Article

Revance Q2 ‍loss per share $0.90​
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - Revance Therapeutics Inc ::Revance releases second quarter 2017 results.Revance Therapeutics Inc - ‍reaffirmed its financial guidance provided in January 2017​.Revance Therapeutics Inc qtrly ‍loss per share $0.90​.Q2 earnings per share view $-0.94 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis

* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS